Table 3.
Diagnostic, therapeutic, and outcome data of the patients with paracoccidioidomycosis from INI-Fiocruz (2010–2019).
| Total n (%) |
Group A (2010–2013) n (%) |
Group B (2014–2019) n (%) |
p-Value | |
|---|---|---|---|---|
| Hospitalizations | 0.003 | |||
| 0 | 114 (67.1) | 52 (81.3) | 62 (58.5) | |
| 1 | 47 (27.6) | 12 (18.8) | 35 (33.0) | |
| 2 | 6 (3.5) | 0 (0.0) | 6 (5.7) | |
| 3 | 3 (1.8) | 0 (0.0) | 3 (2.8) | |
| Treatment 1 | ||||
| Itraconazole | 138 (81.2) | 51 (79.7) | 87 (82.1) | 0.854 |
| SMX-TMP | 76 (44.7) | 27 (42.2) | 49 (46.2) | 0.723 |
| Amphotericin B | 53 (31.2) | 9 (14.1) | 44 (41.5) | 0.001 |
| Fluconazole | 6 (3.5) | 1 (1.6) | 5 (4.7) | 0.411 |
| Sulfadiazine | 3 (1.8) | 1 (1.6) | 2 (1.9) | 1.000 |
| Laboratorial PCM diagnosis 1 | ||||
| Histopathology | 122 (71.8) | 47 (73.4) | 75 (70.8) | 0.841 |
| Direct examination | 40 (23.5) | 9 (14.1) | 31 (29.2) | 0.038 |
| Culture | 44 (25.9) | 10 (15.6) | 34 (32.1) | 0.028 |
| Diagnostic serology | 0.334 | |||
| 1:1–1:4 | 17 (10.0) | 6 (9.4) | 11 (10.4) | |
| 1:8–1:32 | 35 (20.6) | 15 (23.4) | 20 (18.9) | |
| 1:64–1:256 | 35 (20.6) | 9 (14.0) | 26 (24.5) | |
| ≥1:512 | 13 (7.6) | 2 (3.1) | 11 (10.4) | |
| Non reactive | 31 (18.2) | 9 (14.0) | 22 (20.8) | |
| Reactive, titration not performed | 34 (20.0) | 19 (29.7) | 15 (14.2) | |
| Not performed | 5 (2.9) | 4 (6.3) | 1 (0.9) | |
| Outcome | ||||
| Cure | 127 (74.7) | 49 (76.6) | 78 (73.6) | 0.802 |
| Death | 8 (4.7) | 1 (1.6) | 7 (6.6) | 0.261 |
| Lost to follow-up | 31 (18.2) | 14 (21.9) | 17 (16.0) | 0.453 |
| Under treatment | 3 (1.8) | 0 (0.0) | 3 (2.8) | 0.291 |
| Transference 2 | 1 (0.6) | 0 (0.0) | 1 (0.9) |
1 Sum can be greater than 100%, as the same patient can be in more than one category; 2 one patient chose to finish the treatment in another institution; SMX-TMP: sulfamethoxazole with trimethoprim; PCM: paracoccidioidomycosis.